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a  b  s  t  r  a  c  t
Microalgae  are  increasingly  being  utilized  as  food ingredients  for a variety  of applications,  including  as
sources of protein,  egg  and  dairy  substitutes,  and  cooking  oils.  The  dietary  safety  of  a new  structuring  fat
produced  using  a heterotrophic  fermentation  process  by a strain  of  Prototheca  moriformis  was  evaluated
in a 13-week  dietary  toxicity  study  and compared  with  kokum  fat,  a  structuring  fat  of  similar  composition
used  in the  food  industry  and  derived  from  Garcinia  indica  seeds.  The  algal  structuring  fat  was  evaluated
for its genotoxic  potential  using  both  in  vitro  and in  vivo assays.  No treatment-related  adverse  events
occurred  in rats  consuming  algal  structuring  fat or kokum  fat  in the  13-week  study;  no  treatment-related
effects  were  reported  for  body  weight,  food  consumption,  urinalysis,  hematology,  clinical  chemistry,okum
rototheca moriformis
tructuring fat
gross  pathology,  organ  weights,  or histopathology.  While  statistically  signiﬁcant  effects  occurred  in  some
parameters,  none  were  dose-related  or considered  adverse.  Overall,  the NOAELs  for  the  algal  structuring
fat  and  the  kokum  fat were  100  000 ppm,  the  highest  concentrations  tested.  The  algal  structuring  fat  was
not mutagenic  in  the  bacterial  reverse  mutation  assay  in  the  Salmonella  typhimurium  or  Escherichia  coli
strains  tested  and was  not  clastogenic  in  the  in  vivo mouse  bone  marrow  chromosome  aberration  assay.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
There are very few natural fats that have the unique melting
roperties of cocoa butter. The sharp melting proﬁle associated
ith cocoa butter, which approximates human body temperature,
et its ability to remain solid at room temperature, derives from its
igh concentration of structuring fats (i.e., symmetrical monoun-
aturated triglycerides in which oleate (C18:1) occupies the sn-2
Abbreviations: 2-AA, 2-aminoanthracene; AAALAC, Association for Assess-
ent and Accreditation of Laboratory Animal Care International; ANOVA, Analysis
f Variance; AOAC, Association of Analytical Communities; AOCS, American Oil
hemists’ Society; ASTM, American Society for Testing and Materials; bw,  Body
eight; GLP, Good laboratory practice; CPA, Cyclophosphamide; cps, Centipoise;
HA, Docosahexaenoic acid; g, Gram; EPA, Eicosapentaenoic acid; GRAS, Gener-
lly  recognized as safe; GRN, GRAS notiﬁcation; ISO, International Organization for
tandardization; kg, Kilogram; LDL, Low-density lipoprotein; mg,  Milligram; MMS,
ethylmethansulfonate; MTD, Maximum tolerated dose; ppm, Parts-per-million;
-NOPD, 4-nitro-o-phenylene-diamine; NOAEL, No-observed-adverse-effect level;
ECD, Organisation for Economic Cooperation and Development; OSD, Open source
iet; PHOs, Partially hydrogenated oils; RSD, Relative standard deviation; SOS,
tearic-oleic-stearic triglyceride; TAG, Triacylglycerol; TFA, Total fatty acid; US FDA,
nited States Food and Drug Administration.
∗ Corresponding author. Fax: +1 407 802 1405.
E-mail address: rmatulka@burdockgroup.com (R.A. Matulka).
ttp://dx.doi.org/10.1016/j.toxrep.2015.12.006
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
position) in greater than 80% of the triacylglycerol (TAG) species
present [18]. Kokum butter has been evaluated for supplemen-
tation to cocoa butter, but cost still prohibits widespread use of
this fat [13]. While fractionation and hydrogenation processes have
been developed to increase levels of structuring fats in vegetable
and lauric acid-containing (palm kernel) oils and thereby impart
melt proﬁles similar to cocoa butter, their costs of production
are relatively high, their uses limited because of the type of TAG
species found in the starting oil [4], and there are negative health
consequences associated with the generation of trans fats when
hydrogenation is used to make cocoa butter-like fats. Trans fats
have been found to increase low-density lipoprotein (LDL) levels,
increasing the risk of cardiovascular disease [9,15]. Indeed, the food
industry is moving away from the use of trans fats and partially
hydrogenated oils due to an increased understanding of the poten-
tial adverse effects related to their consumption, and the US FDA’s
decision to rescind the Generally Recognized As Safe (GRAS) status
of partially hydrogenated oils (PHOs) [6]. Hence, the search to ﬁnd
replacements and meet additional demand for structuring fats will
only become more challenging.New sources of oils that can either replace or complement
currently available oil sources includes the use of microalgae
that have been found to produce high levels of potentially use-
ful oils [19]. Advances in production and processing have made
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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The bacterial strains (Salmonella typhimurium TA1535, TA1537,
TA98, TA 100 and Escherichia coli WP2  uvrA) utilized for the bacte-24 R.A. Matulka et al. / Toxico
he manufacture of new microalgal-derived oils and ingredients
hrough heterotrophic fermentation more cost-effective. The abil-
ty to genetically engineer certain species of microalgae, as well as
ightly controlling their growing conditions, has resulted in the pro-
uction of oils with well-deﬁned fatty-acid constituents possessing
esirable properties.
Prototheca moriformis is an achlorophyllous (i.e., non-
hlorophyll producing) microalga related to Chlorella protothecoides
aka Auxenochlorella protothecoides)  and is found ubiquitously in
he environment [16]. A strain of P. moriformis was genetically
ngineered as a stable microorganism that produces signiﬁcant
mounts of a new structuring fat containing mostly stearic (∼55%)
nd oleic (∼35%) fatty acids, with minor amounts of other fatty
cids. The resulting fat is composed primarily of triglycerides
>98%), with minor levels of diglycerides and monoglycerides
<2%). This structuring fat produced by this engineered organism
as been produced for use in a variety of food products, but has not
reviously been added to food. The algal structuring fat is similar
o kokum butter, a fat utilized in the European Union (EU) as a
ubstitute for cocoa butter [5].
The typical fatty acid proﬁle for kokum butter is: palmitic
cid (2–6%), stearic acid (50–62%), linoleic (0–2%) and oleic acid
30–42%) [1]. Before introducing a new food ingredient to the mar-
et for human consumption, a demonstration of the safety of that
ngredient must be completed.
To evaluate the dietary safety of the genetically engineered
icroalgal-derived structuring fat produced using a heterotrophic
ermentation process, the structuring fat was assessed for toxicity
n a comprehensive 13-week dietary study in rats and compared to
nother structuring fat containing similar levels of stearate (kokum
at derived from the seeds of Garcinia indica).  No safety information
ould be located in the scientiﬁc literature evaluating the safety
f kokum fat according to current scientiﬁc standards, and this is
lso the ﬁrst scientiﬁc evaluation of the structuring fat produced by
his genetically engineered strain of P. moriformis.  The comparison
as particularly relevant as the algal structuring fat has a fatty acid
nd TAG composition quite similar to kokum [12], yet the latter is
lready consumed in the European Union [5] and in India [7]. An
n vitro mutagenicity study in bacteria (the bacterial reverse muta-
ion study) and the in vivo chromosome aberration assay were also
onducted on the algal structuring fat to evaluate its clastogenic
otential.
. Materials and methods
.1. Test substance and diet preparation
The algal structuring fat (lot # RBD735) is an off-white, reﬁned,
leached, deodorized solid, isolated from a genetically engineered
train of P. moriformis utilizing a unique manufacturing process to
roduce the structuring fat with consistent fatty acid ratios. The
eutral oil is composed of >95% triglycerides, followed by diglyc-
rides (<2%) and monoglycerides (<0.5%). The major fatty acids are
tearic acid (∼55%) and oleic acid (∼35%), as reported as the area
ercent of total fatty acids. Nonsaponiﬁable material is less than
% and the moisture content is approximately 113 ppm (0.01%).
roduct characteristics of the algal structuring fat are provided in
able 1.
A comprehensive screen for toxins was carried out on theil. Pheophorbide A is a naturally-occurring degradation product
f chlorophyll that is associated with photosensitive dermati-
is [10]. Although this organism is achlorophyllous, the test fat
as analyzed for pheophorbide A by high-performance liquid
hromatography with ﬂuorescence detection at UBE Analyti-eports 3 (2016) 123–134
cal Laboratories (Fullerton, CA).1 The fat was also analyzed for
the following algal and cyanotoxins: amnesic shellﬁsh poison-
ing toxins (domoic acid), diarrhetic shellﬁsh poisoning toxins
(okadaic acid, dinophysistoxin-1, pectenotoxin-2, azaspiracid-1,
yessotoxin, and homo-yessotoxin), paralytic shellﬁsh poisoning
toxins (gonyautoxins 1–6; decarbamoylgonyautoxins 2 and 3; sax-
itoxin, decarbamoylsaxitoxin, neosaxitoxin and ciguatoxins 1–4),
cyanobacterial toxins (microcystin-RR, -YR, -LR, -LW, -LF, -LA, -
WR,  -LY and -HtyR and dm-microcystin-RR and -LR), nodularin,
anatoxin and cylindrospermopsin. The algal and cyanotoxin assays
were conducted by liquid chromatography with tandem mass spec-
trometric detection2 at the Food GmbH Jena Analytik - Consulting
(Jena, Germany). No toxins were reported above detection limits
(data not shown).
Diets were formulated using the supplied basal Open Standard
Diet obtained from Research Diets, Inc. (New Brunswick, NJ) to
which kokum and the algal structuring fat were added to achieve
the target doses (with soybean oil as the balance) and to pro-
vide comparable fat, protein and carbohydrate content across dose
groups. All test and control diets were prepared approximately
weekly and stored under refrigeration until used. The concentration
of test substance and the reference kokum, stability and homogene-
ity were evaluated via analysis of the fats in collected feed samples
(samples frozen until assayed).
2.2. Chemicals and materials
Corn oil and cyclophosphamide (CPA) were purchased from
Sigma–Aldrich Corp. (St. Louis, MO)  for the chromosomal aber-
ration assay. Kokum and algal structuring fats were provided by
Solazyme, Inc. (South San Francisco, CA) for the 13-week sub-
chronic dietary study. The kokum fat was obtained from Essential
Wholesale & Labs (Portland, OR). The S9 metabolic activation mix
for the bacterial reverse mutation assay was purchased from Molec-
ular Toxicology, Inc. (Boone, NC) where it was  prepared from livers
of male Sprague-Dawley rats induced with phenobarbital and ben-
zoﬂavone. The bacterial reverse mutation assay positive control
substances, sodium azide (NaN3), ICR 191 acridine, daunomycin,
methylmethanesulfonate (MMS)  and 2-aminoanthracene (2-AA),
were also purchased from Molecular Toxicology, Inc. (Boone, NC),
as well as the overlay agar (supplemented with biotin and limited
amounts of histidine and tryptophan) and minimal glucose agar
plates.
2.3. Animals and organisms
CRL Sprague-Dawley (SD) CD® IGS rats (male and female)
were obtained from Charles River Laboratories (Raleigh, NC) for
the 13-week subchronic dietary study. Veterinarian staff visually
inspected all rats at delivery and during a ﬁve-day acclimation
phase prior to study initiation. The rats were 7–8 weeks of age at
study initiation. Body weight variations remained within ±20% of
the measured mean for both sexes at study start (220.7 g mean for
the males with a range of 220.3–221.5 g and a 182.0 g mean for
the females with a range of 181.7–182.3 g). The rats were individu-
ally housed in suspended stainless steel caging in a temperature
(19–23 ◦C) and humidity (32–55%) controlled room with a 12-h
light/dark cycle. Filtered water and the test diet formulations were
provided ad libitum.rial reverse mutation assays performed at Product Safety Laboratories
1 Limit of detection was 0.5 ppm for pheophorbide A.
2 Limits of detection ranged from 0.0008 to 0.1 g/g in the fat.
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Table  1
Product characteristics for algal structuring fat test material.
Parameter (method) Assay result Parameter (method) Assay result
Compositional properties
Insoluble impurities (AOCS Ca 3a-46) <0.01% Iodine value (internal method) 35.2
Free fatty acids, oleic (AOCS Ca 5a-40) 0.47% Peroxide value (AOCS Cd 8–53) 0 meq/kg
Acid  value (AOCS Ca 5a-40) 0.94 mg  KOH/g p-Anisidine value (ISO 6885) 0.3
Neutral oil (AOCS Ca 9f-57) 99.2% Oxidized triglycerides (IUPAC 2.507 and 2.508) 0.55% (polar basis)
Unsaponiﬁable matter (AOCS Ca 6a-40) 0.63% Polymerized triglycerides (IUPAC 2.507 and 2.508) 0.18% (polar basis)
Triglycerides (AOCS Cd 11d-96) 98.7% Residual hexane (internal method) <1.0
Monoglycerides (AOCS
Cd 11d-96)
<0.01% Elemental analysis (AOCS Ca20–99 and Ca 17–01)
Mercury <0.20 ppm
Diglycerides (AOCS Cd
11d-96)
1.8% Cadmium <0.03 ppm
Chromium <0.02 ppm
Total  polar compounds
(AOCS Cd 20–91)
3.7% Lead <0.20 ppm
Arsenic <0.20 ppm
Fatty  acids (C-M-00036-000)
C16:0 (Palmitic) 4.2 area% TAG proﬁle
C18:0 (Stearic) 55.1 area% Saturate–saturate–saturate <5%
C18:1 (Oleic) 35.0 area% Saturate–unsaturate–saturate >75%
Total  FAMEs identiﬁed 98.8 area% Saturate–oleic–saturate >70%
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•OCS: American Oil Chemists’ Society; ASTM: American Society for Testing and Mate
UPAC:  International Union of Pure and Applied Chemistry; OSI: Oil Stability Index.
PSL; Dayton, NJ) were obtained from Molecular Toxicology, Inc.
Boone, NC).
Euroﬁns BioPharma Product Testing Munich GmbH (Planegg,
ermany) conducted the chromosomal aberration assay using
ale and female NMRI mice from Charles River GmbH (Sulzﬁeld,
ermany) for the in vivo segment. The mice were visually inspected
t delivery and during the acclimation period (minimum of ﬁve
ays) by in-house veterinary staff. The mice were a minimum of
even weeks old at the time of study initiation. The initial body
eights ranged from 31.4 to 38.2 g for the males (9.9% bw variation)
nd 26.2–31.6 g for the female mice (9.6% bw variation). The mice
ere housed by sex (ﬁve animals/cage) in animal rooms environ-
entally controlled (22 ± 3 ◦C and 55 ± 10% relative humidity) and
n a twelve-hour photoperiod. Tap water (sulfur acidiﬁed to ∼pH
.8) and Altromin 1324 maintenance diet (Altromin Spezialfutter
mbH & Co.) were provided ad libitum.
.4. Guidelines
The 13-week rat dietary study design conformed to the follow-
ng guidelines:
Organisation for Economic Co-operation and Development
(OECD) Guidelines for Testing of Chemicals and Food Ingredients,
Section 4 (Test No. 408): Health Effects, Repeated Dose 90-Day
Oral Toxicity Study in Rodents (1998).
U.S. FDA Toxicological Principles for the Safety Assessment of
Food Ingredients, Redbook 2000, IV.C.4.a. (2007).
The bacterial reverse mutation assay was performed in confor-
ance with:
OECD Guidelines for Testing of Chemicals, Section 4 (Test No.
471): “Bacterial Reverse Mutation Test”, adopted July 21st, 1997.
U.S. FDA Redbook. I.V.C.1.a. Short-Term Tests for Genetic Toxicity
(2000): Bacterial Reverse Mutation Test.
The mammalian bone marrow chromosome aberration test was
onducted to comply with:OECD Guidelines for Testing of Chemicals, Section 4, No.
475, “Mammalian Bone Marrow Chromosome Aberration Test”,
adopted July 21st, 1997.FAME: Fatty Acid Methyl Ester; ISO: International Organization for Standardization;
• Commission Regulation (EC) No. 440/2008 B.11:
“Mutagenicity—Mammalian Bone Marrow Chromosome
Aberration Test”, dated May  30, 2008.
• EPA Health Effects Test Guidelines, OPPTS 870.5385 “Mammalian
Bone Marrow Chromosome Aberration Test”, EPA 712-C-98-225,
August 1998.
• First Addendum to OECD Guidelines for Testing of Chemicals,
Section 4, No. 420, “Acute Oral Toxicity—Fixed Dose Procedure”
Adopted December 17, 1998.
• OECD Guidelines for Testing of Chemicals, Section 4, No.
423, “Acute Oral Toxicity—Acute Toxic Class Method” adopted
December 17, 2001.
2.5. Experimental design
2.5.1. Thirteen-week dietary study
The dietary study used to evaluate the potential of the algal
structuring fat or kokum fat to produce toxicity followed well-
established, internationally-accepted protocol guidelines, which
have been utilized to evaluate the potential for toxicological effects
of other algal-based food ingredients [20–22]. Sprague-Dawley
rats (CD® IGS) were randomized to receive a basal control diet
(Group 1, placebo control; n = 20/sex) or one of six test diets
(n = ten/sex/group) formulated to contain either kokum fat at
25 000 ppm (Group 2), 50 000 ppm (Group 3) and 100 000 ppm
(Group 4), or dietary levels of algal structuring fat at 25 000 ppm
(Group 5), 50 000 ppm (Group 6) and 100 000 ppm (Group 7). The
algal structuring fat or kokum fat replaced the soybean oil content
of the basal control diet, such that the test and control diets had
equivalent fat content. The test and control diets were provided
to the rats ad libitum throughout the greater than 90-day study.
Following the treatment period, all surviving rats (fasted ≥ 15 h)
were terminated (by exsanguination) on Days 92/93 (males) or
Days 94/95 (females).
During the study, mortality was  checked twice daily and viabil-
ity, signs of gross toxicity and behavioral changes were observed
once per day during the study. The rats were observed for a battery
of detailed clinical endpoints weekly. Body weights were recorded
twice during acclimation, including just prior to test initiation (Day
0), weekly thereafter, on Days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70,
77, 83, 91 and just prior to terminal sacriﬁce. Because consumption
of oils and fats of this type are not thought to alter neurological
functions, a speciﬁc functional observational batter/motor activity
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Table 2
Hematology, coagulation, and clinical chemistry parameters in male rats following dietary treatment with kokum fat or algal structuring fat.
Parameter Group 1b 0 ppm
(n = 19)
Group 2
25,000 ppm KF
(n = 10)
Group 3
50,000 ppm KF
(n = 10)
Group 4
100,000 ppm KF
(n = 10)
Group 5
25,000 ppm AF
(n = 10)
Group
650,000 ppm AF
(n = 10)
Group 7
100,000 ppm AF
(n = 10)
Hematology—week 12
RBC (106/l) 8.63 ± 0.29 8.61 ± 0.35 8.53 ± 0.33 8.65 ± 0.23 8.55 ± 0.35 8.67 ± 0.36 8.69 ± 0.32
Hemoglobin (g/dl) 15.5 ± 0.5 15.3 ± 0.4 15.4 ± 0.4 15.4 ± 0.5 15.6 ± 0.5 15.3 ± 0.5 15.7 ± 0.5
Hematocrit (%) 45.6 ± 1.4 45.3 ± 1.1 45.7 ± 1.3 45.9 ± 1.4 45.7 ± 1.8 45.4 ± 1.2 46.4 ± 1.8
MCV  (ﬂ) 52.8 ± 1.2 52.8 ± 2.1 53.6 ± 2.5 53.0 ± 1.7 53.5 ± 1.3 52.3 ± 1.2 53.4 ± 0.7
MCH  (pg) 17.9 ± 0.5 17.9 ± 0.8 18.1 ± 0.8 17.9 ± 0.6 18.2 ± 0.6 17.6 ± 0.5 18.1 ± 0.2
MCHC  (g/dl) 34.0 ± 0.5 33.8 ± 0.4 33.7 ± 0.6 33.7 ± 0.5 34.0 ± 0.6 33.7 ± 0.5 33.8 ± 0.4
RDW  (%) 12.7 ± 0.5 12.6 ± 0.7 12.3 ± 0.4 12.2 ± 0.5 12.4 ± 0.5 12.5 ± 0.4 12.3 ± 0.3
Platelet count (103/l) 991 ± 111 999 ± 131 951 ± 182 1086 ± 65 1020 ± 86 1080 ± 119 1077 ± 96
WBC  (103/l) 12.14 ± 2.47 11.55 ± 1.60 11.36 ± 2.72 11.93 ± 1.40 10.96 ± 2.17 12.21 ± 2.43 11.74 ± 1.92
ARET  (103/l) 184.3 ± 27.1 166.6 ± 15.7 167.8 ± 27.9 163.9 ± 33.4 170.6 ± 12.5 167.1 ± 29.1 161.3 ± 19.7
ANEU  (103/l) 2.72 ± 1.38 2.19 ± 0.73 2.21 ± 0.62 2.06 ± 0.62 2.13 ± 0.74 2.53 ± 0.96 2.07 ± 0.68
ALYM (103/l) 8.74 ± 1.66 8.69 ± 1.20 8.47 ± 2.13 9.19 ± 1.29 8.19 ± 1.92 8.93 ± 2.12 8.92 ± 1.39
AMON (103/l) 0.39 ± 0.20 0.35 ± 0.14 0.34 ± 0.10 0.39 ± 0.12 0.35 ± 0.10 0.41 ± 0.09 0.39 ± 0.13
AEOS  (103/l) 0.16 ± 0.09 0.17 ± 0.06 0.21 ± 0.10 0.16 ± 0.06 0.17 ± 0.07 0.20 ± 0.06 0.21 ± 0.10
ABAS  (103/l) 0.06 ± 0.03 0.06 ± 0.03 0.05 ± 0.03 0.05 ± 0.01 0.05 ± 0.02 0.06 ± 0.02 0.07 ± 0.03
ALUC  (103/l) 0.07 ± 0.04 0.08 ± 0.02 0.07 ± 0.04 0.08 ± 0.04 0.08 ± 0.03 0.08 ± 0.03 0.08 ± 0.03
Coagulation—week 13
PT (sec) 10.9 ± 0.3 10.8 ± 0.3 11.0 ± 0.3 10.8 ± 0.3 10.9 ± 0.3 10.9 ± 0.2 11.0 ± 0.4
APTT  (sec) 18.4 ± 2.0 18.7 ± 1.5 21.0 ± 6.2 20.1 ± 2.4 18.2 ± 1.8 19.0 ± 1.8 20.8 ± 4.7
Clinical chemistry—week 12
AST (U/l) 117 ± 111 98 ± 22 77 ± 9 79 ± 21 91 ± 48 75 ± 11 80 ± 12
ALT  (U/l) 47 ± 62 29 ± 12 25 ± 4 32 ± 23 36 ± 26 25 ± 4 27 ± 5
SDH  (U/l) 9.8 ± 10.1 6.2 ± 5.8 6.3 ± 1.5 9.1 ± 4.8 8.0 ± 4.8 6.6 ± 1.0 5.8 ± 1.7
ALKP  (U/l) 95 ± 29 82 ± 24 86 ± 22 93 ± 30 125 ± 55 90 ± 24 102 ± 36
BILI  (mg/dl) 0.14 ± 0.02 0.14 ± 0.03 0.14 ± 0.01 0.14 ± 0.2 0.15 ± 0.02 0.15 ± 0.02 0.15 ± 0.03
BUN  (mg/dl) 12 ± 1 A 11 ± 1 10 ± 1 12 ± 1 11 ± 1 11 ± 1 10 ± 1*
Creatinine (mg/dl) 0.27 ± 0.03 0.29 ± 0.03 0.27 ± 0.03 0.27 ± 0.02 0.27 ± 0.03 0.28 ± 0.04 0.25 ± 0.03
Total  cholesterol (mg/dl) 82 ± 27 87 ± 26 83 ± 20 93 ± 15 83 ± 14 80 ± 17 81 ± 16
Triglycerides (mg/dl) 80 ± 34 72 ± 33 87 ± 46 91 ± 31 88 ± 26 78 ± 25 96 ± 34
Glucose,  fasting (mg/dl) 122 ± 15 128 ± 12 131 ± 17 115 ± 20 118 ± 15 116 ± 17 122 ± 21
Total  protein (g/dl) 6.5 ± 0.2 6.6 ± 0.4 6.5 ± 0.2 6.5 ± 0.2 6.6 ± 0.3 6.5 ± 0.3 6.3 ± 0.4
Albumin (g/dl) 3.1 ± 0.2 3.2 ± 0.2 3.2 ± 0.2 3.1 ± 0.2 3.1 ± 0.2 3.2 ± 0.2 3.0 ± 0.2
Globulin (g/dl) 3.4 ± 0.1 3.4 ± 0.3 3.3 ± 0.1 3.3 ± 0.2 3.5 ± 0.2 3.3 ± 0.2 3.3 ± 0.2
Calcium (mg/dl) 10.1 ± 0.3 9.8 ± 0.4 10.1 ± 0.3 10.2 ± 0.2 10.3 ± 0.4 10.2 ± 0.4 10.1 ± 0.3
Inorganic phosphorus (mg/dl) 6.2 ± 0.5 6.3 ± 0.6 6.1 ± 0.5 6.4 ± 0.5 6.6 ± 0.5 6.4 ± 0.5 6.6 ± 0.3
Sodium (mmol/l) 145.5 ± 7.6 149.9 ± 10.1 142.7 ± 9.0 144.3 ± 9.6 147.1 ± 10.0 142.6 ± 7.3 140.0 ± 4.5
Potassium (mmol/l) 5.01 ± 0.54 5.51 ± 0.86 4.92 ± 0.37 4.72 ± 0.41 5.17 ± 0.48 4.92 ± 0.46 4.89 ± 0.35
Chloride (mmol/l) 104.9 ± 5.4 108.4 ± 7.6 103.5 ± 6.4 104.2 ± 7.1 106.2 ± 7.5 103.9 ± 5.2 102.2 ± 3.8
–
Urinalysis—week 12
Urine volume (ml) 6.8 ± 4.4 3.2 ± 2.6 6.6 ± 2.7 4.3 ± 2.2 4.9 ± 5.6 5.9 ± 3.7 5.9 ± 4.6
pH  6.4 ± 0.5 6.2 ± 0.4a 6.3 ± 0.3 6.2 ± 0.2 6.2 ± 0.3 6.5 ± 0.4 6.1 ± 0.2
Speciﬁc gravity 1.048 ± 0.022 1.069 ± 0.022a 1.046 ± 0.017 1.063 ± 0.019 1.062 ± 0.027 1.048 ± 0.022 1.048 ± 0.018
URO  (EU/dl) 0.3 ± 0.3 0.3 ± 0.3a 0.3 ± 0.3 0.2 ± 0.0 0.4 ± 0.4 0.3 ± 0.3 0.3 ± 0.3
UMTP (mg/dl) 139 ± 74 297 ± 181 183 ± 106 237 ± 104a 167 ± 77a 155 ± 90 157 ± 63
ABAS, absolute basophils; AEOS, absolute eosinophils; AF = algalfat; ALKP, alkaline phosphatase; ALT, alanine aminotransferase; ALUC, absolute large unstained cells; ALYM,
absolute lymphocytes; AMON, absolute monocytes; ANEU, absolute neutrophils; APTT, activated partial thromboplastin time; ARET, absolute reticulocytes; AST, aspartate
aminotransferase; BILI, total bilirubin; BUN, blood urea nitrogen; KF = kokum fat; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration;
MCV,  mean corpuscular volume; PT, prothrombin time; RBC, erythrocytes; RDW, red cell distribution width; SDH, sorbitol dehydrogenase; UMTP, protein; URO, urobilinogen;
WBC,  total white blood cells.
A = Signiﬁcantanalysis of variance.
a
w
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a
i* Statistically signiﬁcant from Group 1 control (P < 0.05).
a n = 9.
b Control group.
ssessment was not conducted. However, a detailed observation
as conducted on a weekly basis that included evaluation for
hanges in gait, posture, and response to handling, as well as the
resence of clonic or tonic movements (e.g., excessive grooming or
epetitive behavior) or bizarre behavior (e.g., self-mutilation, walk-
ng backwards) were recorded. Individual food consumption was
lso recorded weekly and just prior to terminal sacriﬁce on the
ame schedule as body weight measurements. During the acclima-
ion period, the eyes of all rats being considered for the study were
xamined by focal illumination, indirect ophthalmoscopy and,
hen indicated, slit-lamp microscopy. Mydriatic eye drops were
dministered prior to ophthalmoscopy and the eyes were examined
n subdued light; these procedures were repeated on all survivinganimals on Day 88 of the study. Urine samples were collected on
Day 86 and Day 88 for males and females, respectively, from all
surviving animals. The urine was examined for quality, color, clar-
ity, volume, pH, glucose, speciﬁc gravity, protein, ketone, bilirubin,
blood, urobilinogen and microscopic sediments. Blood was  sam-
pled on Day 86 and Day 88 for all surviving males and females,
respectively, for hematology and clinical chemistry analysis, and on
Day 92/93 (males) or Day 94/95 (females) for coagulation assess-
ments for all surviving animals prior to necropsy (Tables 2 and 3).
Blood was collected from all animals for hematology and clin-
ical chemistry analysis by sublingual bleeding under isoﬂurane
anesthesia. Blood samples used to determine the prothrombin
time and the activated partial thromboplastin time (coagulation)
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Table  3
Hematology, coagulation, and clinical chemistry parameters in female rats following dietary treatment with kokum fat or algal structuring fat.
Parameter Group 1d 0 ppm
(n = 19)
Group 2
25,000 ppm KF
(n = 10)
Group 3
50,000 ppm KF
(n = 10)
Group 4
100,000 ppm KF
(n = 10)
Group 5
25,000 ppm AF
(n = 10)
Group 6
50,000 ppm AF
(n = 10)
Group 7
100,000 ppm AF
(n = 10)
Hematology—week 12
RBC (106/l) 8.17 ± 0.28 8.11 ± 0.38 7.93 ± 0.33 8.11 ± 0.46 8.20 ± 0.36 8.16 ± 0.33 8.31 ± 0.21
Hemoglobin (g/dl) 15.3 ± 0.5 15.0 ± 0.6 14.6 ± 0.6* 15.1 ± 0.7 15.2 ± 0.5 15.1 ± 0.6 15.4 ± 0.6
Hematocrit (%) 44.5 ± 1.3 43.9 ± 1.7 42.7 ± 1.8 44.2 ± 1.9 44.9 ± 1.5 44.1 ± 1.4 45.3 ± 1.5
MCV  (ﬂ) 54.6 ± 1.7 54.2 ± 0.7 53.9 ± 1.0 54.6 ± 1.3 54.7 ± 1.7 54.0 ± 1.0 54.6 ± 1.6
MCH  (pg) 18.8 ± 0.6 18.5 ± 0.3 18.4 ± 0.4 18.7 ± 0.6 18.6 ± 0.6 18.5 ± 0.4 18.5 ± 0.5
MCHC  (g/dl) 34.4 ± 0.4 34.2 ± 0.4 34.2 ± 0.4 34.2 ± 0.6 33.9 ± 0.6 34.2 ± 0.4 34.0 ± 0.4
RDW  (%) 11.5 ± 0.4 11.5 ± 0.5 11.5 ± 0.4 11.5 ± 0.3 11.3 ± 0.5 11.5 ± 0.3 11.4 ± 0.2
Platelet  count (103/l) 978 ± 98 1024 ± 101 1027 ± 121 1117 ± 105* 947 ± 77 1033 ± 135 1042 ± 85
WBC  (103/l) 7.61 ± 2.12 8.14 ± 1.48 7.10 ± 1.57 9.37 ± 2.36 8.02 ± 1.02 8.22 ± 1.58 8.89 ± 2.80
ARET  (103/l) 152.5 ± 34.9 146.5 ± 37.2 148.2 ± 30.2 148.9 ± 20.6 164.6 ± 39.5 136.7 ± 26.7 153.1 ± 28.1
ANEU  (103/l) 1.43 ± 0.90 1.39 ± 0.52 1.28 ± 0.23 1.82 ± 0.92 1.62 ± 0.39 1.30 ± 0.64 1.30 ± 0.56
ALYM  (103/l) 5.76 ± 1.26 6.25 ± 1.18 5.44 ± 1.43 6.91 ± 1.88 5.88 ± 0.74 6.43 ± 1.10 7.05 ± 2.31
AMON  (103/l) 0.23 ± 0.09 0.28 ± 0.08 0.20 ± 0.06 0.34 ± 0.08* 0.26 ± 0.08 0.24 ± 0.09 0.27 ± 0.09
AEOS  (103/l) 0.12 ± 0.05 A 0.13 ± 0.03 0.11 ± 0.02 0.18 ± 0.05* 0.15 ± 0.05 0.14 ± 0.03 0.14 ± 0.05
ABAS  (103/l) 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.02 0.03 ± 0.01
ALUC  (103/l) 0.05 ± 0.02 0.07 ± 0.02 0.05 ± 0.02 0.08 ± 0.02 0.07 ± 0.02 0.07 ± 0.02 0.09 ± 0.05
Coagulation—week 13
PT (sec) 10.2 ± 0.2 10.3 ± 0.2 10.3 ± 0.3 10.3 ± 0.3 10.4 ± 0.2 10.4 ± 0.2 10.4 ± 0.2
APTT  (sec) 16.7 ± 1.3 16.1 ± 0.9 17.5 ± 2.0 16.7 ± 1.6 16.2 ± 1.5 16.9 ± 1.4 17.7 ± 2.2
Clinical  chemistry—week 12
AST (U/l) 68 ± 17 63 ± 11 69 ± 10 68 ± 28 67 ± 13 63 ± 9a 63 ± 9
ALT  (U/l) 24 ± 14 18 ± 3 19 ± 2 27 ± 19 21 ± 8 19 ± 4 20 ± 6
SDH  (U/l) 6.9 ± 2.7 6.1 ± 1.5 6.5 ± 2.7 8.6 ± 4.4 7.5 ± 3.8 6.2 ± 1.7a 5.7 ± 0.9
ALKP  (U/l) 47 ± 17 45 ± 15 47 ± 14 52 ± 16 120 ± 210 49 ± 24 40 ± 13
BILI  (mg/dl) 0.17 ± 0.03 0.17 ± 0.03 0.17 ± 0.02 0.16 ± 0.04 0.17 ± 0.03 0.17 ± 0.02 0.17 ± 0.02
BUN  (mg/dl) 12 ± 2 11 ± 2 11 ± 1 11 ± 1 11 ± 2 11 ± 2 10 ± 2
Creatinine (mg/dl) 0.33 ± 0.05 0.34 ± 0.03 0.34 ± 0.05 0.32 ± 0.02 0.34 ± 0.03 0.33 ± 0.03 0.31 ± 0.04
Cholesterol (mg/dl) 90 ± 27 96 ± 23 89 ± 14 99 ± 25 88 ± 23 90 ± 17 89 ± 19
Triglycerides (mg/dl) 68 ± 41 95 ± 71 71 ± 31 90 ± 55 71 ± 31 81 ± 56 63 ± 20
Glucose, fasting (mg/dl) 105 ± 10 113 ± 14 113 ± 21 112 ± 15 113 ± 16 114 ± 15 115 ± 9
Total  protein (g/dl) 7.4 ± 0.5 7.6 ± 0.3 7.4 ± 0.6 7.2 ± 0.7 7.3 ± 0.5 7.4 ± 0.3 7.1 ± 0.4
Albumin (g/dl) 4.0 ± 0.3 4.1 ± 0.2 3.9 ± 0.3 3.8 ± 0.5 4.0 ± 0.3 4.0 ± 0.2 3.8 ± 0.3
Globulin (g/dl) 3.4 ± 0.2 3.5 ± 0.1 3.5 ± 0.3 3.4 ± 0.3 3.4 ± 0.3 3.4 ± 0.2 3.3 ± 0.1
Calcium (mg/dl) 10.6 ± 0.5 10.7 ± 0.2 10.3 ± 0.5 10.6 ± 0.7 10.6 ± 0.5 10.5 ± 0.3 10.5 ± 0.4
Inorganic phosphorus (mg/dl) 5.1 ± 0.9 5.4 ± 0.6 4.4 ± 0.7 5.2 ± 0.6 5.2 ± 0.7 5.1 ± 1.0 5.4 ± 0.5
Sodium (mmol/l) 141.5 ± 3.8 144.0 ± 6.0 142.6 ± 4.4 140.8 ± 4.0 141.8 ± 3.2 141.0 ± 2.6 139.7 ± 1.5
Potassium (mmol/l) 4.22 ± 0.47 4.47 ± 0.38 4.22 ± 0.45 4.42 ± 0.40 4.43 ± 0.40 4.60 ± 0.46 4.42 ± 0.30
Chloride (mmol/l) 101.7 ± 3.1 103.4 ± 4.3 102.9 ± 3.2 101.8 ± 3.0 102.5 ± 2.8 102.1 ± 2.2 101.8 ± 1.1
Urinalysis—week 12
Urine volume (ml) 4.1 ± 3.2b 3.0 ± 2.6 6.3 ± 5.0 6.3 ± 5.7 5.4 ± 4.2 4.1 ± 4.5 5.8 ± 5.2
pH  6.1 ± 0.4c 6.1 ± 0.3 6.1 ± 0.2 6.3 ± 0.5 6.3 ± 0.4 6.3 ± 0.5 6.2 ± 0.3a
Speciﬁc gravity 1.048 ± 0.026c 1.061 ± 0.029 1.033 ± 0.014 1.040 ± 0.024 1.039 ± 0.024 1.048 ± 0.019 1.033 ± 0.018a
URO (EU/dl) 0.3 ± 0.3c 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.3 0.3 ± 0.3 0.2 ± 0.0a
UMTP (mg/dl) 98 ± 126b 115 ± 73 43 ± 26 107 ± 153 56 ± 43 73 ± 40 80 ± 125
ABAS, absolute basophils; AEOS, absolute eosinophils; AF = algalfat; ALKP, alkaline phosphatase; ALT, alanine aminotransferase; ALUC, absolute large unstained cells; ALYM,
absolute lymphocytes; AMON, absolute monocytes; ANEU, absolute neutrophils; APTT, activated partial thromboplastin time; ARET, absolute reticulocytes; AST, aspartate
aminotransferase; BILI, total bilirubin; BUN, blood urea nitrogen; KF = kokum fat; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration;
MCV,  mean corpuscular volume; PT, prothrombin time; RBC, erythrocytes; RDW, red cell distribution width; SDH, sorbitol dehydrogenase; UMTP, protein; URO, urobilinogen;
WBC,  total white blood cells.
A = Signiﬁcant analysis of variance.
* Statistically signiﬁcant from Group 1 control (P < 0.05).
a n = 9.
b n = 18.
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(c n = 17.
d Control group.
ere collected via the inferior vena cava under isoﬂurane anes-
hesia at termination. Gross necropsies were performed on all
tudy rats and selected organs and tissues from the control and
oth high dietary substance groups, as well as organs and tissues
f potential toxicologic interest, which were evaluated histologi-
ally. Evaluation included examination of the surface of the body,
riﬁces, the thoracic, abdominal and cranial cavities and their
ontents. The brain, heart, adrenals (combined), kidneys (com-
ined), spleen, liver, thymus, epididymides (combined), ovaries
combined), uterus with oviducts and testes (combined) were iso-lated and weighed, and organ-to-body weights and organ-to-brain
weights were recorded. Organs and tissues (Tables 4 and 5) from all
animals were preserved in 10% neutral buffered formalin for possi-
ble future histopathological examination. Any organs/tissues that
required further examination were trimmed, processed, embedded
in parafﬁn, sectioned with a microtome, placed on glass micro-
scope slides, stained with hematoxylin and eosin and examined by
light microscopy. Slide preparation and histopathological assess-
ment were performed by a board-certiﬁed veterinary pathologist
at Histo-Scientiﬁc Research Laboratories (Frederick, MD).
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Table 4
Summary of mean terminal body and organ weights in male rats following dietary treatment with kokum fat or algal structuring fat.
Parameter Group 1b 0 ppm
(n = 19)
Group 2
25,000 ppm KF
(n = 10)
Group 3
50,000 ppm KF
(n = 10)
Group 4
100,000 ppm KF
(n = 10)
Group 5
25,000 ppm AF
(n  = 10)
Group 6
50,000 ppm AF
(n = 10)
Group 7
100,000 ppm AF
(n = 10)
Mean terminal body and organ weights—day92/93
Terminal body weight (g) 566.2 ± 56.0 574.8 ± 81.2 595.7 ± 54.5 549.6 ± 78.8 562.1 ± 66.4 575.4 ± 57.5 576.6 ± 52.7
Adrenals (g) 0.0604 ± 0.0100 I1 0.0636 ± 0.0097 0.0631 ± 0.0091 0.0632 ± 0.0132 0.0559 ± 0.0121 0.0604 ± 0.0081 0.0581 ± 0.0103
Brain  (g) 2.277 ± 0.114 I1 2.311 ± 0.127 2.289 ± 0.115 2.273 ± 0.116 2.261 ± 0.096 2.281 ± 0.127 2.227 ± 0.086
Epididymides (g) 1.480 ± 0.133 R2 1.512 ± 0.204 1.544 ± 0.180 1.576 ± 0.161 1.522 ± 0.249 1.413 ± 0.103 1.441 ± 0.314
Heart  (g) 1.647 ± 0.179 I1 1.651 ± 0.204 1.619 ± 0.127 1.555 ± 0.189 1.620 ± 0.141 1.614 ± 0.125 1.592 ± 0.124
Kidneys (g) 3.510 ± 0.413 I1 3.665 ± 0.612 3.778 ± 0.407 3.450 ± 0.453 3.665 ± 0.363 3.478 ± 0.398 3.490 ± 0.353
Liver  (g) 14.102 ± 1.936 I1 13.780 ± 3.179 14.245 ± 1.832 13.436 ± 2.169 13.402 ± 2.167 13.037 ± 1.558 12.777 ± 1.567
Spleen  (g) 0.889 ± 0.151 I1 0.850 ± 0.143 0.885 ± 0.121 0.910 ± 0.129 0.894 ± 0.073 0.857 ± 0.092 0.889 ± 0.118
Testes (g) 3.465 ± 0.269 R2 3.563 ± 0.353 3.555 ± 0.279 3.685 ± 0.262 3.526 ± 0.359 3.526 ± 0.341 3.329 ± 0.882
Thymus (g) 0.2987 ± 0.0975 L3 0.3350 ± 0.0779 0.3443 ± 0.0850 0.2843 ± 0.0806 0.2689 ± 0.0642 0.2766 ± 0.0437 0.3188 ± 0.0863
Organ-to-body weight ratiosa
Adrenals/TBW 0.1081 ± 0.0225 I1 0.1118 ± 0.0197 0.1068 ± 0.0185 0.1155 ± 0.0214 0.1003 ± 0.0218 0.1057 ± 0.0164 0.1012 ± 0.0189
Brain/TBW 4.053 ± 0.390 I1 4.069 ± 0.394 3.870 ± 0.382 4.194 ± 0.489 4.068 ± 0.463 3.991 ± 0.363 3.892 ± 0.392
Epididymides/TBW 2.6314 ± 0.2868 R2 2.6437 ± 0.2915 2.6182 ± 0.4348 2.9178 ± 0.5007 2.7227 ± 0.3946 2.4801 ± 0.3282 2.5245 ± 0.6227
Heart/TBW 2.916 ± 0.266 I1 2.880 ± 0.207 2.728 ± 0.199 2.846 ± 0.248 2.895 ± 0.179 2.818 ± 0.215 2.769 ± 0.172
Kidneys/TBW 6.217 ± 0.633 I1 6.380 ± 0.597 6.364 ± 0.649 6.321 ± 0.702 6.546 ± 0.431 6.066 ± 0.646 6.098 ± 0.840
Liver/TBW 24.896 ± 2.392 R2 23.781 ± 2.499 23.898 ± 2.031 24.555 ± 3.226 23.760 ± 1.659 22.659 ± 1.544** 22.131 ± 1.379***
Spleen/TBW 1.571 ± 0.220 L3 1.483 ± 0.180 1.493 ± 0.216 1.677 ± 0.286 1.607 ± 0.206 1.495 ± 0.150 1.540 ± 0.121
Testes/TBW 6.166 ± 0.693 R2 6.283 ± 0.898 6.019 ± 0.800 6.801 ± 0.895 6.315 ± 0.702 6.189 ± 0.917 5.838 ± 1.702
Thymus/TBW 0.5280 ± 0.1607 R2 0.5872 ± 0.1317 0.5783 ± 0.1439 0.5235 ± 0.1498 0.4781 ± 0.1068 0.4821 ± 0.0707 0.5527 ± 0.1400
Organ-to-brain weight ratiosa
Adrenals/BrW 0.0265 ± 0.0044 I1 0.0275 ± 0.0038 0.0276 ± 0.0042 0.0277 ± 0.0051 0.0246 ± 0.0047 0.0265 ± 0.0037 0.0262 ± 0.0053
Epididymides/BrW 0.6504 ± 0.0540 R2 0.6530 ± 0.0708 0.6735 ± 0.0558 0.6927 ± 0.0537 0.6734 ± 0.1057 0.6218 ± 0.0630 0.6489 ± 0.1447
Heart/BrW 0.724 ± 0.082 I1 0.712 ± 0.072 0.707 ± 0.043 0.684 ± 0.070 0.718 ± 0.068 0.709 ± 0.055 0.716 ± 0.063
Kidneys/BrW 1.541 ± 0.160 I1 1.579 ± 0.188 1.653 ± 0.186 1.516 ± 0.172 1.621 ± 0.142 1.528 ± 0.181 1.568 ± 0.160
Liver/BrW 6.211 ± 0.950 I1 5.918 ± 1.044 6.236 ± 0.861 5.900 ± 0.827 5.930 ± 0.942 5.714 ± 0.569 5.744 ± 0.727
Spleen/BrW 0.391 ± 0.067 I1 0.367 ± 0.051 0.387 ± 0.059 0.401 ± 0.056 0.395 ± 0.029 0.376 ± 0.042 0.399 ± 0.051
Testes/BrW 1.523 ± 0.105 R2 1.544 ± 0.153 1.556 ± 0.137 1.621 ± 0.070 1.561 ± 0.161 1.552 ± 0.196 1.499 ± 0.399
Thymus/BrW 0.1310 ± 0.0397 L3 0.1449 ± 0.0328 0.1496 ± 0.0326 0.1254 ± 0.0364 0.1187 ± 0.0274 0.1210 ± 0.0157 0.1438 ± 0.0416
AF = Algalfat; BrW = Brain weight; KF = Kokum fat; TBW = Terminal body weight.
1[I—Automatic Transformation: Identity (No Transformation)]; 2[R—Automatic Transformation: Rank]; 3[L—Automatic Transformation: Log].
** P < 0.05.
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a Organ-to-body weight ratios and organ-to-brain weight ratio numbers are incr
b Control group.
.5.2. Bacterial reverse mutation assays
The potential for the algal structuring fat to induce gene muta-
ions in bacteria was evaluated using the bacterial reverse mutation
est. The bacterial reverse mutation assay, under the OECD guide-
ines, uses amino acid-requiring strains of S. typhimurium and E.
oli to detect point mutations which involve substitution, addi-
ion or deletion of one or a few DNA base pairs, through the ability
o functionally reverse mutations. The reverse mutations result in
evertant colonies of bacteria with restored capability to synthe-
ize the essential amino acid (e.g., histidine and tryptophan). A
ammalian microsome (S9 fraction) enzyme activation mixture
as utilized in the bacterial culture system to facilitate the con-
ersion of any potential promutagens into active DNA damaging
etabolites.
The S. typhimurium strains TA98, TA100, TA1535 and TA1537
nd E. coli WP2  uvrA (Molecular Toxicology, Inc., Boone, NC) were
sed to determine the ability of the algal structuring fat to induce
utagenicity, either in the absence or presence of the S9 enzyme
ctivation mixture (Molecular Toxicology, Inc., Boone, NC). The
xperiments utilized the standard plate incorporation method
Experiment I) and the pre-incubation method (Experiment II).
he highest test substance concentration used in either study for
ll strains was 5000 g/plate, based on preliminary experiments
sing strains TA98 and TA100 to determine test substance-induced
ytotoxicity and, based on the OECD guideline-indicated limit con-
entration for this test. Six dose levels (1.58, 5.0, 15.8, 50, 158, 500,
580 and 5000 g/plate) were prepared by serial dilution in 0.1%
w/w) Tween-80 in 0.5% (w/v) aqueous methylcellulose (controlby a factor of 1000 for clarity.
vehicle) for Experiment I. Experiment II utilized eight dose lev-
els (40, 80, 160, 320, 640, 1280, 2560 and 5000 g/plate) in the
same control vehicle. Tester strain concentrations of approximately
10
∧
9 cells/ml were used in the experiments (0.1 ml/plate). The
positive control substances for these experiments in the absence of
S9 were: sodium azide (NaN3) for S. typhimurium strains TA100 and
TA1535, ICR 191 acridine for S. typhimurium strain TA1537, dauno-
mycin for S. typhimurium TA98, and MMS  for E. coli strain WP2  uvrA.
In the presence of S9, 2-aminoanthracene (2-AA) was  utilized for all
strains. All of the plates were prepared and evaluated in triplicate.
To be judged positive for mutagenicity, increases in the rever-
tant colonies in the test plates would need to be biologically
relevant (i.e., greater than twice the negative control values for S.
typhimurium TA98, TA100 and/or E. coli WP2  uvrA or greater than
three times the control values for TA1535 and/or TA1537) and/or
dose-dependent. Growth inhibition and the formation of precipi-
tate were also reported, but not considered as mutagenic responses.
No statistical analysis was  conducted.
2.5.3. Chromosome aberration assay
The mammalian in vivo chromosome aberration assay was used
to assess the ability of the algal structuring fat to promote clas-
togenic effects in the mouse model. Bone marrow is the target
tissue because bone marrow is a highly vascularized tissue and
contains rapidly cycling cells that are readily isolated and pro-
cessed. The maximum tolerated dose (MTD) was  determined to
be 2000 mg/kg bw orally in a preliminary range-ﬁnding toxic-
ity experiment. Based on the OECD guidelines, three oral dose
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Table  5
Summary of mean terminal body and organ weights in female rats following dietary treatment with kokum fat or algal structuring fat.
Parameter Group 1a 0 ppm
(n = 19)
Group 2
25,000 ppm KF
(n = 10)
Group 3
50,000 ppm KF
(n = 10)
Group 4
100,000 ppm KF
(n = 10)
Group 5
25,000 ppm AF
(n = 10)
Group 6
50,000 ppm AF
(n = 10)
Group 7
100,000 ppm AF
(n = 10)
Mean terminal body and organ weights—day94/95
Terminal body weight (g) 346.1 ± 43.4 344.3 ± 36.7 334.3 ± 43.9 349.7 ± 43.8 354.0 ± 38.6 338.5 ± 37.7 330.6 ± 28.3
Adrenals (g) 0.0729 ± 0.0120 I2 0.0770 ± 0.0087 0.0712 ± 0.0181 0.0583 ± 0.0147 D1 0.0711 ± 0.0085 0.0698 ± 0.0095 0.0623 ± 0.0142
Brain  (g) 2.126 ± 0.084 I2 2.138 ± 0.073 2.128 ± 0.100 2.107 ± 0.063 2.137 ± 0.071 2.083 ± 0.100 2.082 ± 0.084
Heart (g) 1.117 ± 0.152 L3 1.128 ± 0.094 1.055 ± 0.122 1.090 ± 0.140 1.081 ± 0.112 1.057 ± 0.066 1.038 ± 0.088
Kidneys (g) 2.202 ± 0.240 R4 2.191 ± 0.205 2.213 ± 0.241 2.197 ± 0.499 2.179 ± 0.164 2.068 ± 0.133 2.150 ± 0.205
Liver  (g) 9.025 ± 1.897 L3 8.745 ± 1.641 8.624 ± 1.504 9.191 ± 1.604 9.055 ± 0.907 8.388 ± 0.893 8.315 ± 0.857
Ovaries  (g) 0.0772 ± 0.0187 I2 0.0897 ± 0.0159 0.0796 ± 0.0226 0.0814 ± 0.0253 0.0822 ± 0.0134 0.0804 ± 0.0215 0.0785 ± 0.0191
Spleen (g) 0.613 ± 0.096 I2 0.598 ± 0.054 0.595 ± 0.090 0.668 ± 0.100 0.652 ± 0.065 0.598 ± 0.086 0.604 ± 0.087
Thymus  (g) 0.2750 ± 0.0549 L3 0.2872 ± 0.0629 0.2723 ± 0.1235 0.2997 ± 0.0781 0.2854 ± 0.0793 0.2929 ± 0.0928 0.2953 ± 0.0504
Uterus and Oviduct (g) 0.873 ± 0.355 L3 0.932 ± 0.302 0.822 ± 0.176 0.750 ± 0.180 0.760 ± 0.146 0.900 ± 0.351 0.742 ± 0.203
Organ-to-body weight ratios- Day94/95b
Adrenals/TBW 0.2106 ± 0.0367 0.2245 ± 0.0230 0.2105 ± 0.0410 0.1683 ± 0.0413 D1 0.2032 ± 0.0340 0.2082 ± 0.0321 0.1889 ± 0.0404
Brain/TBW 6.221 ± 0.737 I2 6.266 ± 0.620 6.443 ± 0.702 6.117 ± 0.842 6.094 ± 0.612 6.199 ± 0.491 6.338 ± 0.587
Heart/TBW 3.208 ± 0.354 I2 3.292 ± 0.261 3.169 ± 0.229 3.134 ± 0.338 3.061 ± 0.205 3.140 ± 0.208 3.152 ± 0.280
Kidneys/TBW 6.381 ± 0.6789 R4 6.405 ± 0.702 6.646 ± 0.385 6.372 ± 1.717 6.203 ± 0.655 6.146 ± 0.440 6.519 ± 0.545
Liver/TBW 25.382 ± 2.918 L3 25.289 ± 2.742 25.724 ± 1.815 26.284 ± 3.357 25.677 ± 2.173 24.829 ± 1.470 25.174 ± 1.892
Ovaries/TBW 0.2248 ± 0.0618 I2 0.2647 ± 0.0575 0.2427 ± 0.0775 0.2356 ± 0.0745 0.2326 ± 0.0326 0.2354 ± 0.0449 0.2374 ± 0.0529
Spleen/TBW 1.794 ± 0.282 L3 1.747 ± 0.182 1.791 ± 0.248 1.925 ± 0.303 1.846 ± 0.115 1.767 ± 0.171 1.825 ± 0.193
Thymus/TBW 0.7822 ± 0.1486 R4 0.8331 ± 0.1619 0.8061 ± 0.3053 0.8541 ± 0.1759 0.8076 ± 0.2042 0.8652 ± 0.2611 0.8987 ± 0.1654
Uterus-Oviducts/TBW 2.591 ± 1.056 L3 2.744 ± 1.014 2.488 ± 0.574 2.167 ± 0.564 2.180 ± 0.528 2.675 ± 0.970 2.272 ± 0.675
Organ-to-brain weight ratiosb
Adrenals/BrW 0.0344 ± 0.0058 I2 0.0360 ± 0.0037 0.0334 ± 0.0082 0.0276 ± 0.0067 0.0333 ± 0.0043 0.0335 ± 0.0043 0.0300 ± 0.0073
Heart/BrW 0.525 ± 0.062 I2 0.528 ± 0.041 0.496 ± 0.053 0.517 ± 0.064 0.505 ± 0.042 0.508 ± 0.022 0.499 ± 0.038
Kidneys/BrW 1.036 ± 0.104 R4 1.024 ± 0.076 1.040 ± 0.107 1.040 ± 0.214 1.020 ± 0.068 0.993 ± 0.056 1.033 ± 0.097
Liver/BrW 4.242 ± 0.849 L3 4.086 ± 0.731 4.050 ± 0.658 4.365 ± 0.762 4.238 ± 0.410 4.025 ± 0.351 4.000 ± 0.455
Ovaries  0.0363 ± 0.0085 I2 0.0420 ± 0.0079 0.0374 ± 0.0106 0.0387 ± 0.0123 0.0384 ± 0.0057 0.0385 ± 0.0095 0.0376 ± 0.0085
Spleen/BrW 0.288 ± 0.041 I2 0.280 ± 0.022 0.279 ± 0.033 0.317 ± 0.044 0.305 ± 0.029 0.287 ± 0.036 0.290 ± 0.036
Thymus/BrW 0.1294 ± 0.0253 L3 0.1340 ± 0.0268 0.1283 ± 0.0584 0.1421 ± 0.0364 0.1336 ± 0.0365 0.1406 ± 0.0433 0.1423 ± 0.0268
Uterus-oviducts/BrW 0.412 ± 0.176 L3 0.438 ± 0.147 0.387 ± 0.083 0.355 ± 0.079 0.356 ± 0.068 0.431 ± 0.163 0.357 ± 0.101
AF = Algalfat; BrW = Brain weight; KF = Kokum fat; TBW = Terminal body weight.
1[D—Test Dunnett 2 sided P < 0.05]; 2[I—Automatic Transformation: Identity (No Transformation)]; 3[L—Automatic Transformation: Log]; 4[R—Automatic Transformation:
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b Organ-to-body weight ratios and organ-to-brain weight ratio numbers are incr
evels (400, 1000 and 2000 mg/kg bw)  of the algal structuring
at in corn oil were then used in the main study. The exposure
imes were 24 h and 48 h for the dose groups. Each test sub-
tance and control (corn oil) group included ﬁve male and ﬁve
emale mice, except for the 2000 mg/kg bw dose groups evalu-
ted 48H after administration, which included seven males and
even females. Positive control mice (ﬁve mice/sex) received a
ingle intraperitoneal dose of cyclophosphamide (CPA; 40 mg/kg
w). Four hours before euthanasia (via cervical dislocation), the
etaphase-arresting agent Colcemid® (40 g) was administered
y intraperitoneal injection (i.p.) to all animals. Bone marrow
as obtained from the femurs from treatment and negative
ontrol groups 24 and 48 h after test oil/negative control admin-
stration, and 24 h after treatment of the positive control group
n = ﬁve/sex). The bone marrow cells were ﬁxed, stained and exam-
ned microscopically. Cytogenic damage was assessed by scoring
00 metaphases per animal for structural chromosome aberrations,
uch as breaks, fragments, deletions exchanges and chromosomal
isintegrations. Gaps were recorded but not included in the aberra-
ion rate calculations. Cytotoxicity was evaluated by determining
he mitotic index (% of cells in mitosis) for a minimum of 1000
ells per animal. If a deﬁnite and dose-related increase in aberra-
ion frequency occurred in the test substance-treated groups and
he increase was also biologically relevant in at least one group (i.e.,
reater than the laboratory negative control ranges of 0–5.0% aber-
ant cells in males and 0–3.0% aberrant cells in females), the assay
ould be judged positive for clastogenicity.by a factor of 1000 for clarity.
2.6. Statistical analyses
2.6.1. Thirteen-week dietary study
Mean and standard deviations were calculated for all quanti-
tative data from the in-life, organ weights and clinical pathology
parameters. All experimental groups were compared using a two-
way analysis of variance (ANOVA). Data within groups were
evaluated for homogeneity of variances and normality by Bartlett’s
test, when warranted by sufﬁcient group sizes. Groups treated
with the algal structuring fat or the kokum fat were compared
with the control group by a variety of tests, including Dunn’s
test, Dunnett’s test for multiple comparisons, Kruskal–Wallis non-
parametric analysis of variance, when variances were considered
signiﬁcantly different by Bartlett’s test. Where variances were
considered signiﬁcantly different by Bartlett’s test, groups were
compared using a nonparametric method (Kruskal–Wallis non-
parametric analysis of variance). When non-parametric analysis of
variance was  signiﬁcant, comparison of treated groups to control
was performed using Dunn’s test. Statistical analysis was per-
formed using Provanits® version 9 (Instem LSS, Staffordshire, UK)
and INSTAT Biostatistics, Graph Pad Software, San Diego, CA. Sta-
tistical signiﬁcance was  determined at the 5% level for all analyses.
2.6.2. Chromosome aberration assay
For statistical analysis, the Fisher’s exact test was used with sta-tistical signiﬁcance determined at the 5% level. According to the
OECD guideline, biological relevance was  the primary considera-
tion for the interpretation of the results. Statistical methods were
used only as an aid in evaluating the test result.
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. Results
.1. Test substance and diet preparation
The algal structuring fat was found to be stable under the sug-
ested storage conditions, with a change of 4.6% compared to the
eat substance (as determined by high performance liquid chro-
atography (HPLC)) for the overall test substance stability, which
s within the range of analytical variance of the measured test
ubstance. When mixed into the rat diet and sampled on Day -
 and after 4, 7 and 10 days of storage, the overall stability of
he algal structuring fat was 98.4, 91.3 and 95.4% over a ten-day
eriod for the nominal dietary concentrations of 25 000, 50 000 and
00 000 ppm algal structuring fat in the diet. In addition, a sampling
rom the top, middle and bottom of the dietary preparations found
ll dietary mixtures to be homogeneously distributed, with a rela-
ive standard deviation (RSD) of 2.1, 0.4 and 2.5% between the strata
or the 25 000, 50 000 and 100 000 ppm algal structuring fat concen-
rations, respectively. Concentration veriﬁcation studies showed
hat the algal structuring fat concentrations for Day -3 averaged
05.9, 102.7 and 96.8%; Day 39 resulted in 116.9, 105.5 and 99.8%;
nd Day 88 resulted in 120.6, 107.1 and 99.3% for 25,000, 50,000
nd 100,000 ppm algal structured fat. The higher than expected
ecovery value in the low dose groups for concentration veriﬁca-
ion was not believed to have an impact on this study as the dose
as well tolerated and there were no adverse observations for the
oxicological endpoints evaluated.
Stability testing of the kokum fat test substance found a 7.4%
ifference between Day -3 (99.8%) and Day 84 (107.2%) values (as
etermined by HPLC analysis) under the conditions of the neat
okum storage, within the analytical variance range for the test
ubstance (data not shown). Stability analysis of the kokum fat
fter 4, 7 and 10 days of storage when added to the diet found that
he kokum in the diet was 101.4, 96.7 and 96.7% over the 10-day
eriod for the nominal dietary concentrations of 25 000, 50 000 and
00 000 ppm kokum fat in the diet. The kokum fat was also found to
e homogeneously distributed when sampled from the top, mid-
le and bottom of the dietary preparations, with RSDs of 1.7, 2.0
nd 1.3% for the concentrations of 25 000, 50 000 and 100 000 ppm
okum fat, respectively. Based on the stability, homogeneity and
he concentration veriﬁcation results, the rats were considered to
ave received the targeted concentrations of kokum fat.
.2. Thirteen-week dietary study
No kokum fat- or algal structuring fat-related mortalities
ccurred during the study. One control male was  found dead on
ay 39 of the study, although no adverse clinical ﬁndings were
oted prior to death. The cause of death could not be determined.
ecropsy ﬁndings included a pale liver, multifocal and a mottled
hymus due to hepatocellular vacuolization (lipid, presumptive)
nd thymic hemorrhage (agonal change). One control female was
uthanized on Day 65 for humane reasons, as it was  found to exhibit
ed bilateral ocular discharge, red nasal discharge, gasping, yellow
no-genital staining and a malocclusion of the upper incisors. There
ere no changes in clinical signs or detailed clinical observations
ssociated with the treatment of kokum or algal structuring fat.
There were no changes in weekly body weight or body weight
ain for the treatment groups in either male or female rats that
ere related to kokum fat or algal structuring fat administration
Figs. 1 and 2). Mean weekly and overall (Days 0–91) body weights
nd mean daily body weight gain for both male and female rats
dministered algal structuring fat were comparable to the control
alues for the same sex. The mean weekly body weights and the
verall (Days 0–91) and mean daily body weight gain for the female
ats administered kokum fat were comparable to values for femaleeports 3 (2016) 123–134
controls. The mean weekly body weights for the male rats admin-
istered kokum fat were comparable to values for control male rats.
The overall (Days 0–91) and mean daily body weight gain of males
provided kokum fat was also generally comparable with the con-
trol values, although a signiﬁcant (P < 0.05) decrease in body weight
gain was reported in the high dose kokum fat group on Days 70–77.
Overall (Days 0–91) and mean daily food consumption for both
the male and female rats consuming the algal structuring fat were
not statistically different from the control rats of the same sex. The
overall (Days 0–91) and mean food efﬁciency for the male rats con-
suming the algal structuring fat were comparable with the control
values. There were signiﬁcant decreases in mean food efﬁciency in
the 50 000 ppm male group on Days 28–35 and 70–77, and the male
100 000 ppm dose group on Days 49–56. For the females consum-
ing the algal structuring fat, a signiﬁcant (P < 0.05) decrease in mean
food efﬁciency was reported in the 50 000 ppm dose group. Because
decreased feed efﬁciency was  transient, did not correlate with
decreased body weight, and was not dose-dependent or observed
in other male or female treatment groups, the decreases in food
efﬁciency were considered incidental and not treatment-related.
The overall (Days 0–91) mean daily intake of algal structuring
fat in male rats fed dietary concentrations of 25 000, 50 000 and
100 000 ppm was 1285.6, 2594.3 and 5299.2 mg/kg bw/day, respec-
tively. In female rats, the corresponding mean overall daily intake of
algal structuring fat was 1606.0, 3069.7 and 6313.8 mg/kg bw/day,
respectively. The overall (Day 0–91) mean daily intake of kokum
fat in the male rats fed 25 000, 50 000 and 100 000 ppm was  1308.5,
2525.5, and 5247.3 mg/kg bw/day, respectively. For the female rats
fed the same kokum concentrations, the overall mean daily intake
was 1471.5, 3354.7 and 5943.7 mg/kg bw/day kokum fat, respec-
tively.
Ophthalmoscopic examinations of both eyes of each rat were
conducted prior to study initiation and on Day 88 of the study; one
male in the 25 000 ppm algal structuring fat dose group had chori-
oretinal scarring in the left eye at Day 88. The appearance of the eye
was comparable to a resolved vitreoretinal hemorrhage, a known
sporadic occurrence in Sprague Dawley rats and was  therefore con-
sidered incidental and not treatment-related. All other animals
were normal on ophthalmic exam. There were no test substance-
related changes in urinalysis parameters in male or female rats.
No statistically signiﬁcant differences between control and the
exposed groups or between the different fats were reported for
urinalysis parameters (data not shown).
Evaluation of hematology parameters from Day 86/88
(Tables 2 and 3) for the male and female rats fed algal struc-
turing fat showed no test substance-related effects. There were
no kokum fat-related changes in hematology parameters in male
rats on Day 86. Hematology changes reported in female rats (Day
88) fed 100 000 ppm kokum fat included increases (P < 0.05) in
platelet counts, absolute monocytes and absolute eosinophils in
females only. Although the changes were statistically signiﬁcant
when compared to the control group, the changes were within
the laboratory’s historical control ranges for platelet counts
(502–1651 × 103/l), absolute monocytes (0.04–0.47 × 103/l)
and absolute eosinophils (0.04–0.35 × 103/l) and therefore within
the expected biological variation for this strain and age of rat. There
were no signiﬁcant changes in overall white blood cell counts
or any other hematological or histopathological correlates. The
50 000 ppm female kokum fat dose group exhibited a signiﬁcant
(P < 0.05) decrease in hemoglobin concentration compared to
control females, although the value (14.6 ± 0.6 g/dl) was within
the range of the laboratory’s historical controls for this parameter
(13.4–17.1 g/dl). Because this effect was  not dose-dependent
and was  unaccompanied by any other corresponding clinical or
histopathologic change, the result was considered not toxicolog-
ically relevant. There were no statistically signiﬁcant differences
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n hematology parameters between the algal structuring fat and
okum fat test groups (P > 0.05).
Clinical chemistry values were not different between male
Table 2) or female (Table 3) rats treated with kokum fat, when
ompared to the corresponding control group. A decrease in blood
rea nitrogen (BUN) was  observed in the 100 000 ppm algal struc-
uring fat male dose group; this slight but signiﬁcant (P < 0.05)
ecrease was  within the contract laboratory’s historical control
ange (7–24 mg/dL) and was not toxicologically relevant. When
omparing results from the algal structuring fat dose groups to the
okum fat dose groups, BUN values in males at the 100 000 ppm
lgal structuring fat dose group were lower than values for corre-
ponding dose of kokum fat in the same sex (P < 0.05). However,
ll values were within the laboratory historical control range
7–24 mg/dl) and were considered as being within biological vari-
tion for this strain and age of rats.
There were no macroscopic ﬁndings that were considered
elated to exposure to either the algal structuring fat or to the
okum fat, in either the male or female rats. Fluid-ﬁlled uteri at
ecropsy were found the females of the control group (7/19), the
5 000 ppm kokum group (6/10), and the 100 000 ppm algal struc-
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Fig. 2. Mean body weights of male (m)  and female (f) ratf) rats consuming diets containing kokum fat.
turing fat group (3/10). The ﬂuid ﬁlled uteri usually corresponded
microscopically to luminal dilation of the uterus, attributable to
variations in the estrous cycle in individual animals. As such, this
ﬁnding was not associated with test substance administration. The
remaining macroscopic observations at study termination were of
sporadic incidence and were not related to any trends/patterns
that suggested a relationship to administration of either the algal
structuring fat or kokum fat. The ﬁndings included mild dermal
edema in the ear of one 25 000 ppm kokum fat group male; a
25 000 ppm kokum fat group female with adipose tissue focus,
retroperitoneum, tan, increased ﬁrmness, irregular shape; and
a 50 000 ppm kokum fat group male with adipose tissue focus,
mesentery, round, yellow, ﬁrm, increased ﬁrmness, 2 × 10 mm,
both due to focal steatitis; a 100 000 ppm algal structuring fat group
male with epididymides nodule, right of the tail, yellow, 3 × 3 mm
due to focal sperm granuloma; a 25 000 ppm algal structuring fat
group male with testes soft, left, and epididymides small, left; a
50 000 ppm algal structuring fat group male with testes soft, left,
and epidiymides small, left; a 100 000 ppm algal structuring fat
group male with testes small, bilateral and epididymides small,
bilateral, and another male in the same group with an enlarged
49 56 63 70 77 84 91
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ight testes, 18 × 9 mm,  a small left testes (25 × 12 mm)  and epi-
idymides small, right. All small/soft testes were due to germ cell
egeneration and small epididymides were due to aspermia or
ligospermia and the enlarged testis did not correlate to any histo-
ogic ﬁnding.
A 100 000 ppm kokum fat group female presented with a pale,
iffuse liver with an irregular surface, which correlated to marked
ile duct ectasia, and kidney focus, bilateral, tan, multifocal, pin-
oint with an irregular bilateral, multifocal, diffuse surface due
o cysts in the kidneys. A 100 000 ppm algal structuring fat group
ale had thymus discoloration, multifocal with redness due to ago-
al hemorrhage. In addition, macroscopic ﬁndings occurred which
id not have histologic correlates, including a 100 000 ppm algal
tructuring fat group male with a small left adrenal gland lobe,
 25 000 ppm kokum fat group female with a liver focus on the
ight lateral lobe, 3 × 6 mm;  a 50 000 ppm kokum fat group male
ith a liver focal area indentation on the left lateral lobe (7 mm),
nd a 50 000 ppm algal structuring fat group female with lung dis-
oloration (red) on the left lobe at the cranial aspect (1.5 × 2 cm).
here were no microscopic ﬁndings that were considered related
o exposure to either test substance.
The absolute mean organ weights and mean organ-to-body and
rgan-to-brain weight ratios for the male rats that consumed either
he algal structuring fat or kokum fat were not statistically dif-
erent when compared with the control animals (Table 4). There
ere no algal structuring fat-related changes in absolute or relative
rgan weight changes in either the male or female rats that were
onsidered to be adverse (Table 4, Table 5). Signiﬁcant decreases
n the liver-to-body weight ratios for the 50 000 and 100 000 ppm
lgal structuring fat male dose groups occurred compared to con-
rol males, but these changes were of small magnitude, were not
eﬂected in corresponding decreases in absolute or liver-to-brain
eight, and lacked histopathological or serum chemistry corre-
ates and were therefore of no toxicological relevance. There were
otentially test substance-related decreases (P < 0.05) in the abso-
ute and relative adrenal gland -to-body weight parameters in the
00 000 ppm kokum fat group females (Table 5). However, these
hanges were not associated with histomorphological adrenal ﬁnd-
ngs and were therefore interpreted to be non-adverse in nature.
.3. Bacterial reverse mutation assay
No toxic effects of the algal structuring fat were observed in
ny strain at any dose level. Adequate background lawn growth
as noted on both the control and algal structuring fat-treated
lates. Microbial contamination occurred in one of the three plates
t the 50 g/plate concentration for strain TA1535 in the main test;
his contamination did not affect the validity of the study. Each
train treated with the vehicle control provided mean revertant
olony counts that were within the laboratory historical control
ange and/or published values [14,8]. The positive control sub-
tances caused the expected substantial increases in revertant
olony counts in both the absence and present of the S9 mix  in
he main test. In the conﬁrmatory test, the values for the positive
ontrol for the E. coli strain were adequate when evaluated without
9 activation, but were slightly lower than the expected two-fold
ncrease when evaluated with S9 activation. The same positive con-
rol showed an adequate response in both the presence and absence
f S9 in the main test (data not shown) and therefore, each phase
f the test was considered valid.
The algal structuring fat was solid at room temperature,
lthough maintaining the test substance temperature at 45 ◦C dur-
ng preparation allowed the test substance to be miscible with the
ehicle. Even so, a minimal to heavy precipitate was  observed at
ose levels ≥40 g/plate. The precipitate was present in a dose-
ependent manner and was due to the solid nature of the testeports 3 (2016) 123–134
substance at assay temperature (i.e., a solid fat at room temper-
ature). However, as the average numbers of revertant colonies
for all strains that were incubated with the algal structuring fat
(with or without S9 activation) in both the main and conﬁrmatory
tests were similar to the revertant colony averages for the vehicle
controls, it was  determined that the precipitate did not alter the
system such that it impacted the determination of mutagenicity.
Concentrations of 1.58, 5 and 15.8 g/plate did not result in pre-
cipitate formation, providing an appropriate concentration range
to evaluate mutagenicity. There were no concentration-related or
substantial, biologically relevant test substance-related increases
in the number of revertant colonies (i.e., greater than twice the
negative control for TA98, TA100 or WP2  uvrA or greater than three
times the control values for TA1535 and/or TA1537) observed by
the algal structuring fat in any of the bacterial strains tested either
in the absence or presence of the S9 metabolic activation mix  (data
not shown), when compared to the historical vehicle control data
for these test strains. The control responses in these strains (with-
out S9 mix) were: TA1535 (11–16), TA1537 (7–15), TA98 (26–35),
TA100 (104–117) and WP2  uvrA (24–43) and, with S9 mix the con-
trol ranges were: TA1535 (9–15), TA1537 (9–19), TA98 (38–50),
TA100 (87–123) and WP2  uvrA (38–55). Under the conditions of
the study, the algal structuring fat did not cause gene mutations
by base pair changes or frame shifts in the susceptible genes of the
bacterial strains in this study.
3.4. Chromosomal aberration assay
Exposure to a single oral dose of algal structuring fat for 24 or
48 h did not affect the mean number of chromosomal aberrations
in the bone marrow of the mice of either sex (Table 6). The mean
values noted for the algal structuring fat dose levels of 400, 1000
and 2000 mg/kg bw in the mice (exposed for 24 and 48 h) were
within the historical control data range (0.0–5.0% for male mice
and 0.0–3.0% for female mice). The mitotic index was determined
for each animal and the mean mitotic index was determined for
each test group, which is a supportive endpoint to assess cyto-
toxicity. Male mice exposed to 2000 mg/kg bw for 24 h showed
mean aberrant cell values of 0.2% and female mice exposed for
either 24 or 48 h exhibited no aberrant cells (0.0%). There was
no dose-dependent, biologically relevant increase in chromoso-
mal  aberrations following treatment with the algal structuring fat
(Table 6). For veriﬁcation, the Fisher’s exact statistical test was  per-
formed, which showed that no statistically signiﬁcant (P > 0.05)
change was found when comparing the number of chromosomal
aberrations from the vehicle-dosed animals to those from the algal
structuring fat-dosed animals.
4. Discussion
Consumption of either the algal structuring fat or kokum fat
mixed into the diet for 13 weeks was well-tolerated by the Sprague-
Dawley (SD) CD® IGS rats at all dietary concentrations. There were
no reported treatment-related adverse events in any treatment
group. One control group male rat was found dead on Day 39 with
no adverse clinical ﬁndings noted prior to death, and one control
female was euthanized on Day 65, which exhibited red bilateral
ocular discharge, red nasal discharge, gasping, yellow ano-genital
staining and a had a malocclusion of the upper incisors. No deaths
occurred that were attributable to administration of either test sub-
stance. Daily ingestion of either test fat did not affect any monitored
health or growth parameter, including behavior, appearance, body
weight or weight gain, food consumption or food efﬁciency. Stan-
dard preclinical toxicity endpoints evaluated in this dietary study
included ophthalmology, urinalysis, hematology, clinical chem-
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Table  6
Summary of chromosome aberration assay results for algal structuring fat.
Study groups (n = 5) Metaphases Aberrant cellsa (total/% ± SD) Mean mitotic index Mean body weight (g ± SD)
Negative control, 24 h
Male 500 0/0.0 ± 0.0 7.66 33.2 ± 1.6
Female 500 0/0.0 ± 0.0 8.04 28.3 ± 0.8
Positive control, 24 h
Male 250b 185/74.0 ± 12.3* 1.28 34.3 ± 2.0
Female 300c 107/35.7± 4.9* 1.52** 28.6 ± 1.5
Treatment group (0.2 MTD), 24 h
Male 500 1/0.2 ± 0.4 6.32 35.4 ± 2.4
Female 500 1/0.2 ± 0.4 7.36 27.5 ± 0.9
Treatment Group (0.5 MTD), 24 h
Male 500 1/0.2 ± 0.4 6.66 33.9 ± 1.0
Female 500 0/0.0 ± 0.0 7.78 28.2 ± 0.9
Treatment group (1.0 MTD), 24 h
Male 500 1/0.2 ± 0.4 8.44 34.3 ± 2.1
Female 500 0/0.0 ± 0.0 9.50 29.1 ± 1.2
Negative control, 48 h
Male 500 1/0.2 ± 1.6 6.26 34.0 ± 1.1
Female 500 1/0.2 ± 0.4 9.02 28.6 ± 1.9
Treatment group, 48 h
Male 500 1/0.2 ± 0.4 8.16 35.4 ± 1.5
Female 500 0/0.0 ± 0.0 9.36 27.1 ± 0.7
MTD  = Maximum tolerated dose; SD = Standard deviation.
* P < 0.01, vs. corresponding 24-h negative control group.
** P < 0.05, vs. corresponding 24-h negative control group.
a Aberrant cells, excluding chromosomal gaps.
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stry, gross pathology, organ weights or histopathology. There was
 slight but statistically signiﬁcant decrease in the liver:total body
eight ratios for the male rats that consumed the algal structur-
ng fat; however, there was no signiﬁcant changes in liver:brain
eight ratios for these groups. The body weights for the 50,000 ppm
nd 100,000 ppm algal structuring fat dose groups were slightly
ncreased, resulting in the decreased liver:body weight ratios.
acroscopic observations at study termination were of sporadic
ncidence and were not related to any trends/patterns or of a sta-
istically signiﬁcant or dose-dependent nature that suggested a
elationship to administration of either the algal structuring fat or
okum fat. Any changes to the testes of the male rats consuming the
est articles did not correlate with any microscopic or histological
ndings and was not dose-dependent or statistically signiﬁcant;
herefore, was not considered a causal effect of test article con-
umption. The NOAEL for both the algal structuring fat and the
okum fat was 100 000 ppm, as determined through evaluation
f the toxicological endpoints of this 13-week dietary study. The
00 000 ppm level was the highest dose tested, and was equiva-
ent (on a mg/kg bw/day basis) to a dietary NOAEL for the algal
tructuring fat of 5299.2 mg/kg bw/day and 6313.8 mg/kg bw/day
n the male and female rats, respectively, and a dietary NOAEL for
he kokum fat of 5247.3 mg/kg bw/day and 5943.7 mg/kg bw/day
n the male and female rats, respectively.
The absence of toxicity seen when this novel structuring fat
roduced by a genetically engineered microalgae was  used in this
tudy, is consistent with the evaluation of other microalgal-derived
roducts in subchronic dietary studies, including the 13-week sub-
hronic study of a DHA-rich oil derived from Schizochytrium sp. at
p to 50 000 ppm in the diet (equivalent to 3305 and 3679 mg/kg
w/day in male and female rats, respectively) [17], a 13-week
ietary study of a high lipid-containing whole algal ﬂour prod-
ct from the biomass of C. protothecoides (which resulted in the
etermination of a NOAEL of 4807 mg/kg bw/day in male rats and5366 mg/kg bw/day in female rats) [21], a 13-week dietary study
of a whole algal protein product from the high-protein biomass of
C. protothecoides (which resulted in the determination of a NOAEL
of 4805 mg/kg bw/day in male rats and 5518 mg/kg bw/day in
female rats) [21], a 13-week dietary study of a high oleic acid-
containing oil produced from a genetically engineered strain of P.
moriformis (NOAEL of 5200 and 6419 mg/kg bw/day in male and
female rats, respectively) [22], and a 13-week oral gavage study of a
high eicosapentaenoic acid (EPA)-containing ingredient from Nan-
nochloropsis oculata at up to 2000 mg/kg bw/day [11]. In all of the
studies referenced, the microalgal test substance was  well tolerated
at the highest dose tested; the NOAEL determined from each study
was based on the highest dose provided to the animals. These stud-
ies demonstrate the safety of these food ingredients derived from
microalgae. Similar to the different microalgae-based substances
discussed above, the series of toxicity studies described here con-
ﬁrms that the structuring fat produced from a uniquely engineered
strain of P. moriformis is not toxic when administered in the diet of
rats fed for 13 weeks.
The algal structuring fat examined in the in vitro bacte-
rial reverse mutation assay did not induce mutations in the S.
typhimurium and E. coli strains utilized in the study, when evaluated
at concentrations up to 5000 g/plate, even when precipitation
was formed at ≥40 g/plate. Although high fat concentrations
have been shown to alter the total fatty acid composition of
S. typhimurium cells [3], no alterations from historical control
responses were seen in the current study, indicating that the addi-
tion of the algal structuring fat did not adversely impact the validity
of the study. In addition, oral administration of the algal struc-
turing fat to mice did not induce clastogenic effects in the bone
marrow, a highly vascular tissue with a high production of new
cells that increases the probability of ﬁnding genotoxic responses.
This is consistent with the lack of mutagenic or clastogenic effects
by a high-oleic acid oil produced by P. moriformis [22], a high-lipid
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hole algal ﬂour from C. protothecoides [20], a whole algal protein
rom C. protothecoides [21], or oils produced from Schizochytrium
p., Ulkenia sp. or N. oculata [2,17].
In summary, the evaluation of an algal structuring fat produced
y a unique P. moriformis microalgae in a 13-week dietary toxic-
ty study, as well as studies on the potential of the test substance
o induce mutagenic or clastogenic effects, support the safety for
his algal structuring fat produced using an algal heterotrophic fer-
entation process for use in food. The 13-week toxicity study also
ound that the consumption of kokum fat, a substance with a fatty
cid proﬁle and TAG structure similar to the algal structuring fat,
ut which is already consumed in the EU and India, showed no tox-
city in SD rats when fed at up to 100 000 ppm in the diet. Based
n the 13-week study, the NOAEL for the algal structuring fat was
299.2 mg/kg bw/day in male and 6313.8 mg/kg bw/day in female
ats, and for the kokum fat the NOAEL was 5247.3 mg/kg bw/day
n male and 5943.7 mg/kg bw/day in female rats, the highest doses
valuated.
This is the second study demonstrating the safety of substances
erived from genetically engineered strains of P. moriformis.  In
he ﬁrst study, a 13-week dietary study of high oleic oil from
 different genetically engineered P. moriformis, the NOAEL was
lso 100 000 ppm, which was the highest concentration tested and
here were no mutagenic or clastogenic effects produced by the oil
22]. In the current study, the algal structuring fat produced by an
ngineered strain of P. moriformis had similar safety results. Collec-
ively, these studies on the oils produced from different, genetically
ngineered strains of P. moriformis show that these oils, despite
igniﬁcant differences in their fatty acid composition, TAG compo-
itions and physical properties, support the safety of microalgae
ils for replacement or complementation of vegetable and animal
ils and fats in the human diet.
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